Sinocera 2026H1: Revenue of RMB 2.513 billion, up 16.6%, with the biomedical segment growing 21.96%.

Source: Sinocera Materials 2026 Semi-Annual Report

DentalGoodNews｜On August 6, 2026, Shandong Sinocera Functional Material Co., Ltd. (hereinafter referred to as "Sinocera") released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB 2.513 billion, a year-on-year increase of 16.64%; net profit attributable to shareholders of the listed company reached RMB 363 million, up 9.36% year-on-year; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 361 million, up 12.54% year-on-year.

Source: Sinocera Materials 2026 Semi-Annual Report

In the biomedical materials segment, the company's main products include dental-grade nano-sized composite zirconia powder, zirconia blocks, glass ceramic blocks, and other dental restoration materials. During the reporting period, this segment achieved operating revenue of RMB 534 million, a year-on-year increase of 21.96%; operating costs increased by 28.05% year-on-year; the gross margin was 49.79%, down 2.39 percentage points from the same period last year.

The report disclosed that Sinocera actively seized the policy direction of national rare earth export control, fully leveraged the advantages of domestic rare earth resource supply, and promoted the rapid improvement of production and sales levels in its dental zirconia powder business. Meanwhile, the company adjusted upward the prices of zirconia powder products in line with market supply and demand conditions, further enhancing product profitability. According to previous reports by DENTALGOODNEWS (Leading Dental Industry Media, DGN), Sinocera has raised the sales prices of zirconia powder since July 27, 2026, with increases ranging from approximately 10% to 40%. The company also noted that the impact of price increases on sales volume and the duration of new prices remain uncertain.

Regarding the Upcera Dental business, as of the end of this reporting period, Shenzhen Upcera Dental Technology Co., Ltd. and its subsidiaries held a total of 17 medical device product registrations within their validity period and 5 medical device product filings. During the reporting period, the DUO series products and the high-end aesthetic Aevra blocks continued to expand into overseas markets, with product sales maintaining growth.

In terms of internationalization, Sinocera disclosed that during the reporting period, it acquired 100% equity of Australian dental consumables supplier SDI Limited and its subsidiaries. Upon completion, the company will further advance its globalization process and improve its product portfolio through resource integration and product line complementarity.

Source: Sinocera Materials 2026 Semi-Annual Report

In terms of operations and cash flow, Sinocera's net cash flow from operating activities in the first half of 2026 was RMB 456 million, a year-on-year increase of 36.78%; net cash flow from financing activities was RMB 551 million, up 525.06% year-on-year, mainly due to increased borrowings for the acquisition of Australia's SDI and the implementation of share buybacks; net cash flow from investing activities was RMB -416 million, down 169.67% year-on-year, mainly affected by increased fixed asset investment expenditures.

During the reporting period, the company's administrative expenses increased by 36.86% year-on-year, mainly due to share-based payments and increased intermediary fees for the acquisition of Australia's SDI; R&D investment reached RMB 165 million, up 15.35% year-on-year. As of the end of the reporting period, the company's total assets stood at RMB 10.843 billion, up 14.09% from the end of the previous year; net assets attributable to shareholders of the listed company were RMB 7.330 billion, up 2.49% from the end of the previous year.